WallStSmart

Arcadia Biosciences Inc (RKDA)vsTarget Corporation (TGT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Target Corporation generates 2269285% more annual revenue ($107.70B vs $4.75M). TGT leads profitability with a 4.1% profit margin vs -234.5%. TGT earns a higher WallStSmart Score of 66/100 (B-).

RKDA

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 6.0Quality: 5.3
Piotroski: 3/9Altman Z: -58.76

TGT

Strong Buy

66

out of 100

Grade: B-

Growth: 6.0Profit: 6.0Value: 6.0Quality: 4.5
Piotroski: 3/9Altman Z: 2.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

RKDAUndervalued (+24.4%)

Margin of Safety

+24.4%

Fair Value

$2.30

Current Price

$0.43

$1.87 discount

UndervaluedFair: $2.30Overvalued
TGTUndervalued (+5.3%)

Margin of Safety

+5.3%

Fair Value

$120.98

Current Price

$155.83

$34.85 discount

UndervaluedFair: $120.98Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RKDA2 strengths · Avg: 9.0/10
Price/BookValuation
1.5x10/10

Reasonable price relative to book value

EPS GrowthGrowth
28.5%8/10

Earnings expanding 28.5% YoY

TGT5 strengths · Avg: 8.8/10
EPS GrowthGrowth
100.5%10/10

Earnings expanding 100.5% YoY

Market CapQuality
$70.79B9/10

Large-cap with strong market position

Return on EquityProfitability
24.6%9/10

Every $100 of equity generates 25 in profit

P/E RatioValuation
16.2x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$2.43B8/10

Generating 2.4B in free cash flow

Areas to Watch

RKDA4 concerns · Avg: 2.5/10
Market CapQuality
$1.14M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-323.1%2/10

ROE of -323.1% — below average capital efficiency

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

TGT4 concerns · Avg: 3.3/10
PEG RatioValuation
1.944/10

Expensive relative to growth rate

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Debt/EquityHealth
1.053/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : RKDA

The strongest argument for RKDA centers on Price/Book, EPS Growth.

Bull Case : TGT

The strongest argument for TGT centers on EPS Growth, Market Cap, Return on Equity.

Bear Case : RKDA

The primary concerns for RKDA are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : TGT

The primary concerns for TGT are PEG Ratio, Profit Margin, Debt/Equity. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

RKDA profiles as a turnaround stock while TGT is a value play — different risk/reward profiles.

TGT carries more volatility with a beta of 0.99 — expect wider price swings.

TGT is growing revenue faster at 5.3% — sustainability is the question.

TGT generates stronger free cash flow (2.4B), providing more financial flexibility.

Bottom Line

TGT scores higher overall (66/100 vs 36/100). RKDA offers better value entry with a 24.4% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arcadia Biosciences Inc

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.

Visit Website →

Target Corporation

CONSUMER DEFENSIVE · DISCOUNT STORES · USA

Target Corporation is an American retail corporation. Their retail formats include the discount store Target, the hypermarket SuperTarget, and small-format stores previously named CityTarget and TargetExpress before being consolidated under the Target branding.

Want to dig deeper into these stocks?